IgGenix
PrivateLast Round
Series B
Feb 6, 2023
Total Funding Raised
$75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
IgGenix is a biotechnology company that develops an antibody-based therapeutic platform designed to accelerate clinical responses to allergies by engineering antibodies that effectively capture allergens and enhance immune modulation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IgGenix Comparables
Compare IgGenix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mabylon AG | 83% | |
| Aravax | 79% | |
| Roche Holding | 74% |
IgGenix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 6, 2023 | ||||
| Series A Extension | Jul 27, 2021 | ||||
| Series A | Aug 4, 2020 |
Key People
Founding team and executive leadership
IgGenix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AllerFund | Series A Extension, Series B |
| Medical Incubator Japan | Series B |
| Khosla Ventures | Series B, Series A, Series A Extension |
| Alexandria Venture Investments | Series A Extension, Series B |
| ShangBay Capital | Series A Extension |
| Alexandria Venture Investments | Series A Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 45% MoM, reaching 2.7K.
- Jun 17, 2026
Monthly visitors grew 36% MoM, reaching 1.8K.
IgGenix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about IgGenix's valuation, stock price, and market status.
Is IgGenix a public or private company?
IgGenix is a private company.
What is the current stock price of IgGenix?
IgGenix is a private company with no public stock price. No recent secondary market data is available.
How much is IgGenix worth (valuation)?
Valuation information for IgGenix is not publicly available.
Can I buy IgGenix stock?
IgGenix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was IgGenix's last funding round?
IgGenix's most recent funding round was Series B on February 6, 2023.
Who are the main investors in IgGenix?
Key investors in IgGenix include Khosla Ventures, Alexandria Venture Investments.
Will IgGenix IPO soon?
No public IPO plans have been announced for IgGenix.
How can I track IgGenix secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor IgGenix's secondary market activity and sign up for updates.